President and CEO
Mr. Vardzel has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several smallto-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.
Amelia Wall Warner, PharmD, RPh
Chief Operating Officer
Dr. Amelia Warner founded Global Specimen Solutions, Inc. in 2013 with the vision of radically improving translational science through powerful new pipeline data management analytics. Prior to GSS, Amelia served as CEO, President and Director of the Board for Gentris Corporation, where she led a financial and operational turnaround resulting in the successful sale of Gentris to a public company. Amelia served as the Head of Clinical Pharmacogenomics and Clinical Specimen Management for Merck Research Laboratories (MRL). She oversaw all clinical pharmacogenomics projects, as well as policies and procedures for biosample collection and storage for clinical trial samples; she also served as the MRL Pharmacogenomics Expert for the Translational Science Research Network. She was the MRL Key Expert for Global Regulation for Genetic Research and Human Specimen Usage Regulation/Law. She served as Chair of the Industry Pharmacogenomics Working Group (I-PWG) and a PhRMA Representative to ICH E16- Genomic Biomarkers Related to Drug Response. Amelia completed a Residency in Pediatric Pharmacotherapy at St. Jude Children’s Research Hospital and a Fellowship in Clinical Pharmacology/Pharmacogenomics at St. Jude Children’s Research Hospital with William Evans, PharmD. Amelia holds a BS in Biology from Wake Forest University and a PharmD from the University of North Carolina at Chapel Hill.
Arlette H. Uihlein, MD, FCAP, FASCP
Vice President, Operations, Pathology Services & Medical Director
Dr. Arlette Uihlein serves as the Vice President Pathology Services and Medical Director of Helomics®. Dr. Uihlein is Board Certified in Anatomic and Clinical Pathology, Cytopathology and Family Medicine. Dr. Uihlein completed her Pathology Residency at Allegheny General Hospital, where she served as Chief Resident in Pathology and completed Fellowships in Cytopathology and Surgical Pathology. She has conducted extensive clinical research involving molecular markers and imaging in solid tumors, and novel applications of cellular tumor markers. Dr. Uihlein received her B.S. from Baldwin-Wallace College and her Doctor of Medicine degree from The Medical College of Ohio. She is a Designated Civil Surgeon for the U.S. Dept. of Justice and a certified Medical Review Officer for the Department of Transportation. She is a Fellow of the College of American Pathologists and the American Society of Clinical Pathology, NYSDOH Certificate Qualified, and a member of ASCO.
Mark A. Collins PhD
Chief Innovation Officer
Dr. Collins has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.
Vice President, Finance
Mr. Young serves as the Vice President of Finance and Controller of Helomics. Michael has over twenty years of experience in accounting and finance operations and management within various industries and has held senior financial positions with Aspen Dental Management Inc., BlueRock Energy Inc. and Keystone Dedicated Logistics. Michael joined Helomics in February of 2017 and has been tasked with overseeing accounting and finance as well as billing and reimbursement. Michael received his Bachelor of Business Administration Degree in Accounting from Niagara University and holds a Master of Business Administration from LeMoyne College.
Vice President, Human Capital
Sarah Fanks serves as the Vice President Human Capital of Helomics®. Sarah has over twenty years of experience in human resources within the healthcare and IT industry. Formerly, Sarah served as the Human Resources Manager for an IT consulting firm during the mergers between, Comsys / Cotelligent / Pittsburgh Business Consultants, which provided business solutions that supported the gap between people and information. Prior to moving into the Human Capital domain, Sarah was an Investment Administrator for a Pension / Investment / Retirement Planning organization. Sarah earned her Master of Science in Human Resources Management from the La Roche College and Bachelor of Science in Business Management from the University of Phoenix. Sarah is a certified professional PHR and SHRM-CP.